Identification
- Summary
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is an influenza antigen used in seasonal influenza vaccines.
- Generic Name
- Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
- DrugBank Accession Number
- DB14385
- Background
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) unknown W45Z4CJE2J Not Available Not applicable - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Fluarix Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/59/2007 (H1N1) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) Suspension Intramuscular GlaxoSmithKline Biologicals SA 2009-07-16 2009-07-15 US 
Fluarix 2010/2011 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) Suspension Intramuscular GlaxoSmithKline Biologicals SA 2010-08-09 2010-08-02 US FluVaccinol Subunit Tetra Injektionssuspension in einer Fertigspritze Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 mcg/0.5ml) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated) (15 mcg/0.5ml) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen (formaldehyde inactivated) (15 mcg/0.5ml) + Influenza B virus B/Massachusetts/2/2012 BX-51B hemagglutinin antigen (formaldehyde inactivated) (15 mcg/0.5ml) Injection, suspension Intramuscular Mylan österreich Gmb H 2017-11-15 Not applicable Austria 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 166D8OWM7B
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Basic Science Influenza A Subtype H5N1 Infection 1 4 Completed Other Asthma 1 4 Completed Prevention Flu caused by Influenza 8 4 Recruiting Basic Science Coronavirus Disease 2019 (COVID‑19) / Lymphoma 1 4 Terminated Basic Science Flu caused by Influenza 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Intramuscular Injection, suspension Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at July 05, 2018 18:02 / Updated at May 14, 2021 01:06